Seattle’s life sciences sector has long boasted top-tier research institutions like the University of Washington and the Fred Hutchinson Cancer Center. The region ranks fourth in venture capital funding for biotech. The decision by Pfizer to acquire Seattle Genetics for $43 billion reflects the region’s ability to develop innovative companies that build value. We spoke to Luke Timmerman, founder and editor of The Timmerman Report, about the strengths of the Seattle biotech region, the ecosystem for industry to grow there, and the key challenges it faces.
